Find → Understand → Decide
Acasunlimab in combination with pembrolizumab and standard chemotherapy (in separate expansion cohorts)
Discovery priority: MEDIUM · POSSIBLE / INVESTIGATE
Discovery priority ≠ investment recommendation. These are observation labels, not verified canonical products. Buyer qualification: UNKNOWN.
Why investigate?
Why stranded (event context): portfolio pruning
Why now: Historical lead requires current reconfirmation; no fresh transaction catalyst established
Company/trial failed before biology? UNKNOWN
Biology implicated: UNCLEAR · Failure context: CORPORATE/FINANCIAL
MODEL INFERENCE · LOW confidence. Explicit asset-linked program event or documented experimental trial arm, stop scope, dated recency and biological cautions; no publication count or buyer-gate input.
Current control: UNKNOWN · Restart: UNKNOWN · Development reuse: UNKNOWN
Next diligence: Confirm present program status and exact product identity, then trace scoped rights/data/CMC and review arm-level human outcomes.
Existing buyer gates
Human Signal: UNKNOWN
Cheap Truth: UNKNOWN
Clean Rights: UNKNOWN
Market Pull: UNKNOWN
No event or publication count supplies missing gate evidence. Existing reviewed opportunities remain in their original records.
Evidence timeline
2026-09-09 · trial:NCT03917381
Registry update date, not proven program-stop date
SOURCE TEXT · Exact source
Genmab has decided to discontinue further clinical development of acasunlimab following strategic portfolio prioritization. The decision was not related to safety concerns.
Trial reason is not attributed to every intervention; comparator/combination context needs review.
Interpretation: portfolio pruning · AUTO_INFERRED · MEDIUM
Provenance and retrieval scope
{
"hash": "3592fc96b9f5d748c993d4c57aff6b9ae7c6e2c0d66d6cf08daed45bd2f00870",
"metadata": {
"complete": false,
"content_hash": "79a6fba92b66700138ae221547e71d5ac170eb0a4445be6331d6b6a474f18df6",
"failed": false,
"last_checked": 1790026980.9308648,
"last_success": 1790026980.9308648,
"live_verified": true,
"scope": "AREA[OverallStatus]TERMINATED AND AREA[StartDate]RANGE[2015-01-01,2026-09-21] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL)"
},
"path": "protocolSection.armsInterventionsModule.interventions",
"raw_hash": "79a6fba92b66700138ae221547e71d5ac170eb0a4445be6331d6b6a474f18df6",
"raw_path": "research/obz7_sources/79a6fba92b66700138ae221547e71d5ac170eb0a4445be6331d6b6a474f18df6.json",
"request_params": {
"countTotal": "true",
"format": "json",
"pageSize": 100,
"query.term": "AREA[OverallStatus]TERMINATED AND AREA[StartDate]RANGE[2015-01-01,2026-09-21] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL)",
"sort": "LastUpdatePostDate:desc"
},
"request_url": "https://clinicaltrials.gov/api/v2/studies",
"type": "clinicaltrials",
"url": "https://clinicaltrials.gov/study/NCT03917381"
}Freshness is claim-specific
Fetching an old filing today does not establish current ownership or program status.
pipeline · PARTIAL · Not independently refreshed for current scoped claim · checked UNKNOWN
sec · PARTIAL · Not independently refreshed for current scoped claim · checked UNKNOWN
rights · PARTIAL · Not independently refreshed for current scoped claim · checked UNKNOWN
contact · PARTIAL · Not independently refreshed for current scoped claim · checked UNKNOWN
patent_assignment · PARTIAL · Not independently refreshed for current scoped claim · checked UNKNOWN
clinicaltrials · STALE · AREA[OverallStatus]TERMINATED AND AREA[StartDate]RANGE[2015-01-01,2026-09-21] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL) · checked 2026-09-21T21:43:00.930865+00:00
Registry observations (1)
NCT03917381 · TERMINATED · PHASE1, PHASE2 · Solid Tumors · Trial sponsor Genmab
Reported aliases: GEN1046; DuoBody®-PD-L1x4-1BB. Identity, treatment role and exposure require review.